Prophylactic chemotherapy with fosfomycin trometamol salt during transurethral prostatic surgery: a controlled multicenter clinical trial.
A prospective, randomized controlled study was carried out in 24 Italian urology wards in 675 patients undergoing transurethral prostatic resection, utilizing three different chemoprophylactic treatments with either amoxycillin (AMX), co-trimoxazole (CTX) or fosfomycin trometamol salt (FT) in order to prevent postoperative urinary tract infections. FT significantly lowered the incidence of both postoperative bacteriuria and symptomatic infections in comparison to AMX and CTX. Transient side effects, mild or moderate, were observed in 6.6% of cases. Similar safety and protective results were obtained in 233 patients undergoing different transurethral instrumentations who were chemoprophylactically treated with FT.
D000617:Aminoglycosides / Q000627:therapeutic use; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004338:Drug Combinations / Q000627:therapeutic use; D005578:Fosfomycin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011292:Premedication; D011446:Prospective Studies; D011468:Prostatectomy; D011897:Random Allocation; D013420:Sulfamethoxazole / Q000627:therapeutic use; D013530:Surgical Wound Infection / Q000517:prevention & control*; D013997:Time Factors; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014552:Urinary Tract Infections / Q000517:prevention & control*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D005578:Fosfomycin; D000658:Amoxicillin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole